Brian Turpin

Brian Turpin

Auto-generated profile, based on publicly available information

Brian Turpin

Cincinnati Children's Hospital Medical Center

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Cell Reports
Verified
Journal Article
Open access
ABAndrew S Brohl
Andrew S Brohl
SSSivasish Sindiri
Sivasish Sindiri
JWJun S. Wei
Jun S. Wei
David MilewskiDavid Milewski
David Milewski
HCHsien-Chao Chou
Hsien-Chao Chou
JKJaved Khan
Javed Khan
We perform an immunogenomics analysis utilizing whole-transcriptome sequencing of 657 pediatric extra-cranial solid cancer samples representing 14 diagnoses, and additionally utilize transcriptomes of 131 pediatric cancer cell lines and 147 normal tissue samples for comparison. We describe patterns of infiltrating immune cells, T cell receptor (TCR) clonal expansion, and translationally relevant immune checkpoints. We find that tumor-infiltrating lymphocytes and TCR counts vary widely across cancer types and within each diagnosis, and notably are significantly predictive of survival in osteosarcoma patients. We identify potential cancer-specific immunotherapeutic targets for adoptive cell therapies including cell-surface proteins, tumor germline antigens, and lineage-specific transcription factors. Using an orthogonal immunopeptidomics approach, we find several potential immunotherapeutic targets in osteosarcoma and Ewing sarcoma and validated PRAME as a bona fide multi-pediatric cancer target. Importantly, this work provides a critical framework for immune targeting of extracranial solid tumors using parallel immuno-transcriptomic and -peptidomic approaches.

5 September 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
CDChristopher E Dandoy
Christopher E Dandoy
TKTammy Kelley
Tammy Kelley
AGAditya H. Gaur
Aditya H. Gaur
RNRajaram Nagarajan
Rajaram Nagarajan
KDKathy Demmel
Kathy Demmel
ABAmy L. Billett
Amy L. Billett

Verified
Journal Article
Open access
PDF file
HPHolly Pacenta
Holly Pacenta
WAWendy Allen-Rhoades
Wendy Allen-Rhoades
DLDavid Langenau
David Langenau
PHPeter Houghton
Peter Houghton
CKCharles Keller
Charles Keller
TLTheodore Laetsch
Theodore Laetsch
Rhabdomyosarcoma is the most common soft tissue sarcoma diagnosed in children and adolescents. Patients that are diagnosed with advanced or relapsed disease have exceptionally poor outcomes. The Children’s Oncology Group (COG) convened a rhabdomyosarcoma new agent task force in 2020 to systematically evaluate novel agents for inclusion in phase 2 or phase 3 clinical trials for patients diagnosed with rhabdomyosarcoma, following a similar effort for Ewing sarcoma. The task force was comprised of clinicians and basic scientists who collectively identified new agents for evaluation and prioritization in clinical trial testing. Here, we report the work of the task force including the framework upon which the decisions were rendered and review the top classes of agents that were discussed. Representative agents include poly-ADP-ribose polymerase (PARP) inhibitors in combination with cytotoxic agents, mitogen-activated protein kinase (MEK) inhibitors in combination with type 1 insulin-like growth factor receptor (IGFR1) inhibitors, histone deacetylase (HDAC) inhibitors, and novel cytotoxic agents.

4 November 2018 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
BTBrian Turpin
Brian Turpin
JPJoseph G. G Pressey
Joseph G. G Pressey
RNRajaram Nagarajan
Rajaram Nagarajan
BWBrian D. Weiss
Brian D. Weiss
ATAndrew T. Trout
Andrew T. Trout
RDRoshni Dasgupta
Roshni Dasgupta

23 September 2023 in Cancer
Verified
Journal Article
Open access
MJMichael E. Johnston
Michael E. Johnston
ZFZishaan Ahmed Farooqui
Zishaan Ahmed Farooqui
RNRajaram Nagarajan
Rajaram Nagarajan
JPJoseph G. G Pressey
Joseph G. G Pressey
BTBrian Turpin
Brian Turpin
RDRoshni Dasgupta
Roshni Dasgupta
Background: Technetium‐99 (99mTc) lymphoscintigraphy with blue dye injection is an accepted method for sentinel lymph node (SLN) mapping, but blue dye has known adverse effects, and injection of 99mTc may increase time under anesthesia for pediatric patients. Indocyanine green (ICG) may serve as an adjunct to assist with visibility and identification of SLNs. We hypothesized that sensitivity of ICG was similar to blue dye in SLN biopsies.Methods: Thirty patients (36 procedures with 96 total specimens) underwent preoperative intradermal injection of 99mTc, followed by intradermal injection of isosulfan blue and ICG. Test characteristics of blue dye, ICG, and 99mTc included sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).Results: ICG had a sensitivity of 87% and PPV of 83% for detection of 99mTc‐hot lymph nodes; blue dye had a sensitivity of 44% and PPV of 97%. For detection of pathologically confirmed lymph nodes, ICG had a sensitivity of 84% and a positive predictive value (PPV) of 91%. 99mTc had a sensitivity of 82% and a PPV of 94%. ICG had no significant difference in odds of being positive in pathology‐confirmed lymph nodes compared to 99mTc (odds ratio [OR], 0.818; 95% confidence interval [CI], 0.3–2.172; p = .823) and had higher odds than isosulfan blue (OR, 0.025, 95% CI, 0.001–0.148; p < .001).Conclusion: This study established the efficacy of ICG as an adjunct to SLNB in the pediatric and young adult population. ICG was safe, more efficacious than blue dye, and may obviate the need for lymphoscintigraphy in selected patients resulting in reduced time under anesthesia.

3 February 2015 in Pediatric Radiology
Verified
Journal Article
Closed access
PDF file
ATAndrew T. Trout
Andrew T. Trout
SSSusan E. Sharp
Susan E. Sharp
BTBrian K. Turpin
Brian K. Turpin
BZBin Zhang
Bin Zhang
MGMichael J. Gelfand
Michael J. Gelfand